NCT01121393 2018-12-14BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)Boehringer IngelheimPhase 3 Completed364 enrolled 28 charts 1 FDA
NCT00949650 2018-04-06BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationBoehringer IngelheimPhase 3 Completed345 enrolled 23 charts 1 FDA
NCT00525148 2016-09-16LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating MutationsBoehringer IngelheimPhase 2 Completed129 enrolled 18 charts 1 FDA